(NASDAQ: ARTL) Artelo Biosciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.34%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.48%.
Artelo Biosciences's earnings in 2026 is -$13,465,000.On average, 3 Wall Street analysts forecast ARTL's earnings for 2026 to be -$23,421,274, with the lowest ARTL earnings forecast at -$22,502,793, and the highest ARTL earnings forecast at -$24,110,135. On average, 3 Wall Street analysts forecast ARTL's earnings for 2027 to be -$12,567,513, with the lowest ARTL earnings forecast at -$12,074,669, and the highest ARTL earnings forecast at -$12,937,146.
In 2028, ARTL is forecast to generate $29,990,656 in earnings, with the lowest earnings forecast at $28,814,552 and the highest earnings forecast at $30,872,734.